泽璟制药-U
(688266)
| 流通市值：262.41亿 | | | 总市值：262.41亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 167,641,962.39 | 532,954,371.3 | 384,117,191.62 | 240,696,731.58 |
| 营业收入 | 167,641,962.39 | 532,954,371.3 | 384,117,191.62 | 240,696,731.58 |
| 二、营业总成本 | 224,891,718.58 | 726,897,941.91 | 509,620,185.43 | 330,471,226.37 |
| 营业成本 | 19,467,832.72 | 36,991,445.8 | 27,024,454.43 | 17,495,980.98 |
| 税金及附加 | 752,388.88 | 1,448,782.82 | 867,445.09 | 563,957.23 |
| 销售费用 | 94,063,802.54 | 271,447,660.35 | 189,668,174.67 | 120,194,067.03 |
| 管理费用 | 15,073,925.75 | 58,187,706.06 | 41,035,357.09 | 26,420,304.17 |
| 研发费用 | 102,236,990.94 | 387,998,981.13 | 272,787,045.8 | 181,154,578.04 |
| 财务费用 | -6,703,222.25 | -29,176,634.25 | -21,762,291.65 | -15,357,661.08 |
| 其中:利息费用 | 7,205,839.97 | 28,892,922.3 | 21,794,742.26 | 15,346,029.69 |
| 其中:利息收入 | 14,056,559.81 | 58,287,813.71 | 43,673,487.35 | 30,781,852.03 |
| 加:公允价值变动收益 | - | 3,919,137.25 | 3,902,701.58 | 3,613,934.1 |
| 加:投资收益 | 432,028.59 | 2,939,351.7 | 2,407,009.09 | 1,561,941.83 |
| 资产处置收益 | 3,080,043.7 | - | - | - |
| 信用减值损失(新) | 279,528.06 | -3,758,982.85 | -3,158,148.94 | -3,059,245.63 |
| 其他收益 | 23,441,133.52 | 35,800,880.73 | 9,803,330.56 | 8,221,905.16 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -30,017,022.32 | -155,043,183.78 | -112,548,101.52 | -79,435,959.33 |
| 加:营业外收入 | - | 3,681.42 | 3,681.42 | 884.96 |
| 减:营业外支出 | 300,000 | 8,304.43 | 58,304.43 | 58,301.69 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -30,317,022.32 | -155,047,806.79 | -112,602,724.53 | -79,493,376.06 |
| 减:所得税费用 | -1,003,660.05 | -4,749,483.88 | -2,956,159.52 | -1,965,711.71 |
| 六、净利润 | -29,313,362.27 | -150,298,322.91 | -109,646,565.01 | -77,527,664.35 |
| 持续经营净利润 | -29,313,362.27 | -150,298,322.91 | -109,646,565.01 | -77,527,664.35 |
| 归属于母公司股东的净利润 | -28,262,235.13 | -137,830,775.59 | -97,902,983.29 | -66,536,070.99 |
| 少数股东损益 | -1,051,127.14 | -12,467,547.32 | -11,743,581.72 | -10,991,593.36 |
| (一)基本每股收益 | -0.11 | -0.52 | -0.37 | -0.25 |
| (二)稀释每股收益 | -0.11 | -0.52 | -0.37 | -0.25 |
| 八、其他综合收益 | 140,191.46 | -8,749,199.69 | 26,035,078.95 | 338,774.7 |
| 归属于母公司股东的其他综合收益 | 138,889.09 | -8,524,610.6 | 24,168,674.87 | 284,879.39 |
| 九、综合收益总额 | -29,173,170.81 | -159,047,522.6 | -83,611,486.06 | -77,188,889.65 |
| 归属于母公司股东的综合收益总额 | -28,123,346.04 | -146,355,386.19 | -73,734,308.42 | -66,251,191.6 |
| 归属于少数股东的综合收益总额 | -1,049,824.77 | -12,692,136.41 | -9,877,177.64 | -10,937,698.05 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |